Skip to main content
Clinical Trials/JPRN-UMIN000022213
JPRN-UMIN000022213
Completed
未知

The association of Cytokine /chemokine profiles with the clinical outcome and safety in relapsed/refractory multiple myeloma patients treated with lenalidomide plus dexamethasone - Cytokine /chemokine profiles in relapsed/refractory multiple myeloma patients treated with lenalidomide plus dexamethasone

Hamamatsu University School of Medicine0 sites20 target enrollmentMay 11, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple myeloma
Sponsor
Hamamatsu University School of Medicine
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2016
End Date
March 31, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\.Previous treatment with lenalidomide 2\.Hypersensitivity to lenalidomide and/or dexamethasone 3\.non\-secretory myeloma, solitary plasmacytoma, plasma cell leukemia, of POEMS syndrome 4\.Positivity of HBs antigen or, HCV or HIV antibody 5\.Uncontrollable liver dysfunction, renal dysfunction, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, hypertension and infection 6\.Double cancer requiring treatments 7\.Psychoneurotic disorder, depression state or history 8\.Patients with pregnancy, patients who may be pregnant, or patients during lactation 9\.Pulomonary fibrosis, interstitial pneumonitis or interstitial shadow on chest CT, even if no symptom 10\.Ineligible patient by physicians decision

Outcomes

Primary Outcomes

Not specified

Similar Trials